<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vitj</journal-id><journal-title-group><journal-title xml:lang="ru">Врач и информационные технологии</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Doctor and Information Technologies</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1811-0193</issn><issn pub-type="epub">2413-5208</issn><publisher><publisher-name>Pirogov National Medical and Surgical Center</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25881/18110193_2024_2_68</article-id><article-id custom-type="elpub" pub-id-type="custom">vitj-51</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Математическая модель для прогнозирования снижения расчетной скорости клубочковой фильтрации через 12 месяцев после паратиреоидэктомии у пациентов с первичным гиперпаратиреозом</article-title><trans-title-group xml:lang="en"><trans-title>A mathematical model for predicting the decline in estimated glomerular filtration rate at 12 months after parathyroidectomy in patients with primary hyperparathyroidism</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елфимова</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Elfimova</surname><given-names>A. R.</given-names></name></name-alternatives><email xlink:type="simple">ainetdinova.alina@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Еремкина</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Eremkina</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н.</p></bio><bio xml:lang="en"><p>PhD</p></bio><email xlink:type="simple">eremkina.anna@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Реброва</surname><given-names>О. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Rebrova</surname><given-names>O. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н.</p></bio><bio xml:lang="en"><p>DSc</p></bio><email xlink:type="simple">o.yu.rebrova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ковалева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovaleva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н.</p></bio><bio xml:lang="en"><p>PhD</p></bio><email xlink:type="simple">kovaleva.elena@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мокрышева</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Mokrysheva</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, член-корр. РАН</p></bio><bio xml:lang="en"><p>DSc, professor, Corresponding Member of the RAS</p></bio><email xlink:type="simple">mokrisheva.natalia@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГНЦ РФ ФГБУ «НМИЦ эндокринологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГНЦ РФ ФГБУ «НМИЦ эндокринологии» Минздрава России; ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre; Federal State Autonomous Educational Institution of Higher Education «N.i. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>08</month><year>2024</year></pub-date><volume>0</volume><issue>2</issue><fpage>68</fpage><lpage>81</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елфимова А.Р., Еремкина А.К., Реброва О.Ю., Ковалева Е.В., Мокрышева Н.Г., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Елфимова А.Р., Еремкина А.К., Реброва О.Ю., Ковалева Е.В., Мокрышева Н.Г.</copyright-holder><copyright-holder xml:lang="en">Elfimova A.R., Eremkina A.K., Rebrova O.Y., Kovaleva E.V., Mokrysheva N.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vit-j.ru/jour/article/view/51">https://www.vit-j.ru/jour/article/view/51</self-uri><abstract><p>Актуальность. Первичный гиперпаратиреоз (ПГПТ) – эндокринное заболевание, характеризующееся избыточной продукцией паратгормона (ПТГ) и повышенным или верхненормальным уровнем кальция крови, обусловленного первичной патологией околощитовидных желез (ОЩЖ). «Классическим» осложнением ПГПТ является снижение фильтрационной функции почек. Паратиреоидэктомия (ПТЭ) снижает риски дальнейшего ухудшения фильтрационной функции, однако в ряде случаев этого не достигается.Цель. Разработать математическую модель для прогнозирования ухудшения расчетной скорости клубочковой фильтрации (рСКФ) через 12 месяцев после ПТЭ у пациентов с ПГПТ, выполнить её программную реализацию. Материалы и методы. Ретроспективное исследование включало 140 пациентов с ПГПТ, которым была проведена ПТЭ в 1993–2010 и 2018–2020 гг. в ГНЦ ФГБУ «НМИЦ эндокринологии» Минздрава России. Анализировались пол, возраст, показатели фосфорно-кальциевого, пуринового, липидного, углеводного обменов, наличие осложнений ПГПТ, прием терапии по поводу ПГПТ, гистологическое исследование удаленной ткани ОЩЖ, развитие послеоперационной гипокальциемии и транзиторного гипопаратиреоза, терапия послеоперационной гипокальциемии. Для построения математической модели использовали метод случайный лес.Результаты. Для прогнозирования снижения рСКФ построена модель, использующая 24 предиктора: пол, возраст, индекс массы тела, ПТГ, кальций ионизированный, щелочная фосфатаза, фосфор, мочевина, рСКФ, общий холестерин, диастолическое артериальное давление, SD(T-кр.)&lt;-2,5/SD(Z-кр.)&lt;-2,0, ХБП, длительность нефролитиаза, прием блокаторов рецепторов ангиотензина-II и ангиотензинпревращающего фермента, предоперационный прием колекальциферола и цинакальцета, гиперплазия/аденома ОЩЖ, послеоперационная гипокальциемия, доза альфакальцидола и препаратов кальция, послеоперационный прием колекальциферола. Полученная модель (http://194.87.111.169/cfr) прогнозирует снижение рСКФ у пациентов с ПГПТ после ПТЭ с вероятностью 56,8–86,3% и исключает с вероятностью 85,6–97,7%.Выводы. Разработана математическая модель для прогнозирования снижения рСКФ через 12 мес. после ПТЭ у пациентов с ПГПТ, общая точность которой составила 88%, 95% ДИ(79%; 93%). Модель программно реализована в виде калькулятора, который может использоваться в рутинной клинической практике</p></abstract><trans-abstract xml:lang="en"><p>Background. Primary hyperparathyroidism (PHPT) is an endocrine disease characterized by excessive production of parathyroid hormone (PTH) and elevated or high-normal blood calcium levels caused by primary pathology of the parathyroid glands. The "classic" complication of PHPT is a decrease in the kidneys filtration function. Parathyroidectomy (PTE) reduces the risks of further deterioration in filtration function; however, in some cases, this is not achieved.Aim. To develop a mathematical model to predict the decline in estimated glomerular filtration rate (eGFR) 12 months after PTE in patients with PHPT, and implement it as a software.Methods. Retrospective study included 140 patients with PHPT who underwent PTE in 1993–2010 and 2018–2020 at the National Medical Research Center of Endocrinology. Analyzed variables included sex, age, indicators of calciumphosphorus, purine, lipid, and carbohydrate metabolism, presence of PHPT complications, treatment for PHPT, histological examination of removed parathyroid tissue, development of postoperative hypocalcemia and transient hypoparathyroidism, therapy for postoperative hypocalcemia. The random forest method was used to build the mathematical model.Results. To predict the decline in eGFR, a model using 24 predictors was built: sex, age, body mass index, PTH, ionized calcium, alkaline phosphatase, phosphorus, urea, eGFR, total cholesterol, diastolic blood pressure, SD(T-score)&lt;-2.5/ SD(Z-score)&lt;-2.0, CKD, duration of nephrolithiasis, use of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors, preoperative use of cholecalciferol and cinacalcet, parathyroid hyperplasia/adenoma, postoperative hypocalcemia, dose of alfacalcidol and calcium supplements, postoperative use of cholecalciferol. The resulting model (http://194.87.111.169/cfr) predicts a decline in eGFR in patients with PHPT after PTE with a probability of 56.8–86.3% and excludes – with a probability of 85.6–97.7%.Conclusion. A mathematical model to predict the decline in eGFR 12 months after PTE in patients with PHPT was developed, with an overall accuracy of 88%, 95% CI (79%; 93%). The model was implemented as a calculator that can be used in routine clinical practice</p></trans-abstract><kwd-group xml:lang="ru"><kwd>первичный гиперпаратиреоз</kwd><kwd>скорость клубочковой фильтрации</kwd><kwd>паратиреоидэктомия</kwd><kwd>моделирование</kwd></kwd-group><kwd-group xml:lang="en"><kwd>primary hyperparathyroidism</kwd><kwd>glomerular filtration rate</kwd><kwd>parathyroidectomy</kwd><kwd>modeling</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья опубликована в рамках выполнения государственного задания «Оптимизация Российского электронного реестра пациентов с первичным гиперпаратиреозом» НИОКТР 121030100032-7 при финансовой поддержке Министерства здравоохранения Российской Федерации</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Мокрышева Н.Г. Околощитовидные железы. – Медицинское информационное агентство, 2019.</mixed-citation><mixed-citation xml:lang="en">Mokrysheva N.G. Okoloshchitovidnye zhelezy. Meditsinskoe informatsionnoe agentstvo, 2019 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Рубрикатор клинических рекомендаций. Первичный гиперпаратиреоз. Доступно по: http://cr.rosminzdrav.ru/schema/88_4.</mixed-citation><mixed-citation xml:lang="en">Rubrikator klinicheskih rekomendacij. Pervichnyj giperparatireoz. Available from: http://cr.rosminzdrav.ru/schema/88_4. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мокрышева Н.Г., Рожинская Л.Я., Перетокина Е.В., и др. Анализ основных эпидемиологических характеристик первичного гиперпаратиреоза в России (по данным регистра) // Проблемы эндокринологии. – 2012. – Т.58. – №5. – С.16-20. (In Russ.)] doi: 10.14341/probl201258516-20.</mixed-citation><mixed-citation xml:lang="en">Mokrysheva NG, Rozhinskaia LI, Peretokina EV, et al. The results of analysis of the major epidemiological characteristics of primary hyperparathyroidism in Russia based on the registry data. Problems of Endocrinology. 2012; 58(5): 16-20. (In Russ.) doi: 10.14341/probl201258516-20.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Walker MD, Nickolas T, Kepley A, et al. Predictors of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2014; 99(5): 1885-92. doi: 10.1210/jc.2013-4192.</mixed-citation><mixed-citation xml:lang="en">Walker MD, Nickolas T, Kepley A, et al. Predictors of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2014; 99(5): 1885-92. doi: 10.1210/jc.2013-4192.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney int. 2020; 98(4S): S1-115. doi: 10.1016/j.kint.2020.06.019.</mixed-citation><mixed-citation xml:lang="en">KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney int. 2020; 98(4S): S1-115. doi: 10.1016/j.kint.2020.06.019.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney int. 2011; 80(1): 17-28. doi: 10.1038/ki.2010.483.</mixed-citation><mixed-citation xml:lang="en">Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney int. 2011; 80(1): 17-28. doi: 10.1038/ki.2010.483.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">GBD CKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225): 709-733. doi: 10.1016/S0140-6736(20)30045-3.</mixed-citation><mixed-citation xml:lang="en">GBD CKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020; 395(10225): 709-733. doi: 10.1016/S0140-6736(20)30045-3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Рубрикатор клинических рекомендаций. Остеопороз. Доступно по: https://cr.minzdrav.gov.ru/schema/87_4.</mixed-citation><mixed-citation xml:lang="en">Rubrikator klinicheskih rekomendacij. Osteoporoz. Available from: https://cr.minzdrav.gov.ru/schema/87_4. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nelson HD, Haney EM, Chou R, et al. Screening for Osteoporosis: Systematic Review to Update the 2002 US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul. Report No.: 10-05145-EF-1.</mixed-citation><mixed-citation xml:lang="en">Nelson HD, Haney EM, Chou R, et al. Screening for Osteoporosis: Systematic Review to Update the 2002 US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul. Report No.: 10-05145-EF-1.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bonnick S. Bone Densitometry in Clinical Practice. Humana Press; 2004.</mixed-citation><mixed-citation xml:lang="en">Bonnick S. Bone Densitometry in Clinical Practice. Humana Press; 2004.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Scientific Group Technical Report. Assessment of osteoporosis at the primary health-care level. Technical Report. 2007. Available from: https://frax.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf.</mixed-citation><mixed-citation xml:lang="en">WHO Scientific Group Technical Report. Assessment of osteoporosis at the primary health-care level. Technical Report. 2007. Available from: https://frax.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Рубрикатор клинических рекомендаций. Хроническая болезнь почек (ХБП). Доступно по: https://cr.minzdrav.gov.ru/recomend/469_2.</mixed-citation><mixed-citation xml:lang="en">Rubrikator klinicheskih rekomendacij. Hronicheskaya bolezn' pochek (HBP). Available from: https://cr.minzdrav.gov.ru/recomend/469_2. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Molnar C. Interpretable Machine Learning. A Guide for Making Black Box Models Explainable. 2023.</mixed-citation><mixed-citation xml:lang="en">Molnar C. Interpretable Machine Learning. A Guide for Making Black Box Models Explainable. 2023.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005; 26(4): 97-122.</mixed-citation><mixed-citation xml:lang="en">Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005; 26(4): 97-122.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Walker MD, Dempster DW, McMahon DJ, et al. Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab. 2012; 97(5): 1501-7. doi: 10.1210/jc.2011-3072.</mixed-citation><mixed-citation xml:lang="en">Walker MD, Dempster DW, McMahon DJ, et al. Effect of renal function on skeletal health in primary hyperparathyroidism. J Clin Endocrinol Metab. 2012; 97(5): 1501-7. doi: 10.1210/jc.2011-3072.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tassone F, Guarnieri A, Castellano E, et al. Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2015; 100(8): 3069-73. doi: 10.1210/jc.2015-2132.</mixed-citation><mixed-citation xml:lang="en">Tassone F, Guarnieri A, Castellano E, et al. Parathyroidectomy Halts the Deterioration of Renal Function in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2015; 100(8): 3069-73. doi: 10.1210/jc.2015-2132.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Nair CG, Babu M, Jacob P, et al. Renal dysfunction in primary hyperparathyroidism; effect of Parathyroidectomy: A retrospective Cohort Study. Int J Surg. 2016; 36(Pt A): 383-7. doi: 10.1016/j.ijsu.2016.11.009.</mixed-citation><mixed-citation xml:lang="en">Nair CG, Babu M, Jacob P, et al. Renal dysfunction in primary hyperparathyroidism; effect of Parathyroidectomy: A retrospective Cohort Study. Int J Surg. 2016; 36(Pt A): 383-7. doi: 10.1016/j.ijsu.2016.11.009.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Daumé H. A Course in Machine Learning. Self-published; 2015.</mixed-citation><mixed-citation xml:lang="en">Daumé H. A Course in Machine Learning. Self-published; 2015.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fallah F. Hierarchical Quadratic Random Forest Classifier. 2023. arXiv:2306.01893.</mixed-citation><mixed-citation xml:lang="en">Fallah F. Hierarchical Quadratic Random Forest Classifier. 2023. arXiv:2306.01893.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Marco TR, Sameer S, Carlos G. Why Should I Trust You? Explaining the Predictions of Any Classifier. 2016. arXiv:1602.04938.</mixed-citation><mixed-citation xml:lang="en">Marco TR, Sameer S, Carlos G. Why Should I Trust You? Explaining the Predictions of Any Classifier. 2016. arXiv:1602.04938.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
